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Background: Beyond the need for harmonizing deﬁnitions, a number of factors
can impact on and/or hamper comparisons between registries and even within
registries over time (exhaustivity rate, genetic background, availability of specialized
diagnostic tools, CF NBS, quality of care . . . ).
Aim: Using data from the Belgian CF Registry over a 10-y period (2007: n = 1.047,
1998: n = 564), we aimed to compare important characteristics of registered patients.
Results: There were signiﬁcant increases in the proportions of adults
(38.8 to 49.3%, p< 0.0001), patients diagnosed >18 y (4.2 to 7.7%, p = 0.003),
PS patients (6.2 to 12.9%, p< 0.0001), patients with intermediate sweat chloride val-
ues (30−60mmol/L) (1.2 to 9.1%, p< 0.0001). The percentage of patients homozy-
gous for the F508del mutation (F508delH) decreased (54.9 to 46.9%, p = 0.001).
In 2007, 51.7% of non-transplanted children (6−<18 y) had a FEV1 90% pred
(Knudson) vs 32.3% in 1998 (p< 0.0001) but this improvement was more marked
for PS patients (33.3 to 75%) than for F508delH (32.2 to 43.4%).
Conclusion: Deriving from each national annual report a parallel report focusing
on patients homozygous for the F508del mutation would limit some pitfalls
encountered when trying to compare data from different countries and allow more
meaningful longitudinal analysis of outcomes in a given country. Additional costs
would be negligible.
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CF and particularly CFTR-RD provide a challenge for molecular diagnostic because
of many unclassiﬁed variants (UV) and identical genotypes associated with different
phenotypes. There is a need for an accurate and exhaustive collection of sequence
variations identiﬁed in patients suffering from disease related with the CFTR gene as
most of these variants reside in genetic testing laboratories and remain unpublished.
Since 2009, we have collected and curated molecular and minimal clinical data
from 9 French expert laboratories. Using the Universal Mutation Database (UMD®)
software, we have constructed the UMD-CFTR-France, an exhaustive and manually-
curated database, dedicated to sequence variations of the CFTR gene identiﬁed
in CF and CBAVD patients, in patients analysed in the context of newborn
screening, chronic rhinosinusitis, bronchiectasy, pancreatitis, nasal polyposis, fetal
bowel anomalies, and compound heterozygous unaffected parents.
This database currently contains molecular data on 2426 patients: 1837 CF and
589 CFTR-RD mostly represented by CBAVD (490). Besides disease-causing
mutations, it contains UVs and non-pathogenic polymorphisms (532 different
variants) representing 7488 entries.
Pooling of these data could signiﬁcantly advance the interpretation of rare variants
and the analysis of correlations between genotype/haplotype and phenotype. The
strength of this interpretation and analysis is based on the large number of high
quality data and dedicated bioinformatics tools.
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The German CF quality assurance project was established in 1995. The overall
aim is to improve quality of life and survival in CF patients. Data collection is
an essential tool in this quality management process. From the beginning data
collection was achieved electronically. Since 2008 a new speciﬁc database is under
development. Aim of this work is to create a software allowing not only the
collection of patient data but also the management of medical and administrative
process in the outpatient clinic. Information on routine clinical and lab data,
bacteriology, therapy and speciﬁc outcomes on local and national level are available.
The system is implemented in a client-server-aplication. The server allocates the
central database (Oracle). The software should optimize performance of storage,
search and analyzing data on patients with CF. In 2008 7,644 patients have been
treated in 93 centres. The annual return was improved to 84%. Demographic,
nutritional and lung function data are given and speciﬁed for the centres. Mortality
analysis and longitudinal data are included. Comparison of patient data between
different centres and national registry has been done. The data is also provided
anonymously to the ECFS registry.
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Actuality: 57 patients with cystic ﬁbrosis (CF) are evaluated and treated in Clinic
of Pneumology, Republic of Moldova.
Aim: In this work we assessed the peculiarities of genetic ﬁndings, clinical
symptoms and explorative picture in children with CF from Republic of Moldova.
Materials and Methods: This study included 29 boys, 28 girls, mean age
8.91±0.45 years. Genetic diagnosis was realized in children and their parents for
4−8 CFTR mutations (F508del, R334W, N1303, G551D, R347P, R553X, R117H,
W1282X, G542X). More rare mutations were revealed in Center of Bordeaux.
The evaluation program for CF patients include: anthropometry, chest radiography,
computed tomography (CT), spirography, sputum bacteriology, serum biochemistry,
coprology.
Results: F508del mutation was revealed in 57.8% cases (inclusive 24.5% −
homozygotes), 1 child − N1303K, 1 case − R334W. In Bordeaux were discovered
mutation in 4 children (F508del/296+1G>C, F508del/185+1G>T, G542X/N1303K,
128+1G>A/1677delTA). The mean age of CF diagnosis was 2.65±0.05 years: at
the age of <1 year in 52.6% children, 1−5 year − 38.5% children, 5−10 years −
7.1% cases, 10−18 years − 8.7% children, 19 years − 1.7% cases. Ps. aeruginosa
was isolated in 47.3% cases. CT has revealed bronchiectasis (34.3% cases),
pulmonary ﬁbrosis (23.8% cases) and chronic bronchitis (68.8% cases). Spirography
showed pulmonary function impairments (FVC − 65.8±2.2%, FEV1 − 68.8±2.6%).
Nutrition impairment was established in 71.5% CF patients.
Conclusion: Lung affecting and nutrition problems are present in most children with
CF from Moldova. There is a prevalence F508del CFTR mutation in CF patients
in Moldova.
